Charles Riv Labs Intl Inc Stock Price, News & Analysis

Charles River Laboratories (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus have announced a strategic collaboration to develop and manufacture Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in chimeric antigen receptor (CAR) T-cell therapies targeting hematological cancers.

The Gates Institute will leverage Charles River’s expertise in cell and gene therapy CDMO services to support its mission of advancing cellular and gene therapies. This partnership will utilize Charles River's manufacturing platforms and services, including process development, phase-appropriate research-grade and High-Quality plasmid DNA production, and GMP LVV manufacturing. Materials produced will support an upcoming Investigational New Drug (IND) application for Phase I clinical trials.

Charles River aims to expedite clinical and commercial manufacturing through standardized protocols and optimized methods, reducing development time and costs while ensuring high-quality production. This collaboration aligns with Charles River’s efforts to expand its cell and gene therapy portfolio and simplify complex supply chains.

Charles River Laboratories and Captain T Cell have announced a strategic alliance for the production of plasmid DNA and viral vectors to support T-cell immunotherapy clinical trials. This collaboration, part of Charles River's Cell and Gene Therapy (CGT) Accelerator Program, will leverage Charles River's extensive CDMO capabilities to aid Captain T Cell's development of TCR-T cell therapies for solid tumors. Captain T Cell focuses on creating T cells equipped with advanced tumor-specific receptors to treat patients whose tumors are unresponsive to existing treatments. Charles River's well-established production capabilities will streamline Captain T Cell's path from pre-clinical to commercial scale, aimed at enhancing the availability and efficacy of T-cell immunotherapies for cancer patients.

Charles River Laboratories (NYSE: CRL), in collaboration with MatTek , has secured a $1.3 million grant from the Foundation for Chemistry Research & Initiatives (FCRI) to develop a New Approach Methodology (NAM) for inhalation toxicology, aiming to reduce the reliance on animal testing. This multidisciplinary project involves Charles River’s Edinburgh team, MatTek’s in vitro EpiAirway™ model, dosimetry modeling by Battelle, and consultancy from Greek Creek Toxicokinetics. The initiative is part of Charles River's Alternative Methods Advancement Project (AMAP) and supported by the American Chemistry Council’s Long-Range Research Initiative (ACC LRI). The goal is to enhance chemical safety assessments and regulatory evaluations through innovative, non-animal testing methods.

Charles River Laboratories (NYSE: CRL) has announced the opening of a new Charles River Accelerator and Development Lab (CRADL®) facility in Somerville, Massachusetts. This AAALAC-accredited site provides flexible vivarium and laboratory space, addressing the growing demand within Massachusetts' biopharmaceutical sector. Strategically co-located with Nest.Bio, the new facility offers scalable contract vivarium space and access to Charles River's comprehensive drug discovery and non-clinical development resources. The facility's unique setup includes private lab suites, rentable lab benches, and office space on the same floor, fostering efficient communication and productivity. This is the fourth CRADL site in Massachusetts, joining nearly 30 facilities worldwide. The grand opening event is scheduled for July 31, 2024.

Charles River Laboratories (NYSE: CRL) has announced a collaboration with Sanofi to develop Virtual Control Groups (VCGs) in nonclinical toxicology. This initiative aims to reduce the use of animals in research by replacing some control group animals with data-driven virtual counterparts created from historical datasets. Guided by Charles River’s Alternative Methods Advancement Project (AMAP), this collaboration leverages machine learning and extensive data to generate meaningful study results without the need for as many animal subjects. The project is a pioneering effort to apply VCGs, commonly used in clinical trials, to preclinical research, involving partnerships with regulatory and biopharmaceutical leaders. The initiative aims to advance sustainable science in toxicology studies.

Charles River Laboratories (NYSE: CRL) will present at two upcoming conferences. The company will speak at the William Blair 44th Annual Growth Stock Conference on June 4th at 10:00 a.m. CT (11:00 a.m. ET) and at the Jefferies Global Healthcare Conference on June 5th at 10:00 a.m. ET. Management will discuss the company's strategic priorities, business developments, and industry trends. Live webcasts and replays will be available on the Investor Relations section of Charles River's website.

Charles River Laboratories has launched new Modular and Fast Track viral vector technology transfer frameworks. These frameworks are designed for seamless tech transfer to its Maryland-based viral vector Center of Excellence within nine months. The Fast Track framework allows for straightforward transfers when no process changes are needed, while the Modular framework supports complex transfers requiring process modifications. Both frameworks aim to prevent costly delays and ensure program success. Charles River's CoE offers full-scale capabilities for adeno-associated virus, adenovirus, lentivirus, and retrovirus production and integrates their concept-to-cure portfolio from discovery to commercialization.

Charles River Laboratories reported first-quarter 2024 results with revenue of $1.01 billion, GAAP EPS of $1.30, and Non-GAAP EPS of $2.27. The company updated its 2024 guidance and reaffirmed revenue growth and non-GAAP earnings per share estimates. Despite revenue declines in the DSA segment, the RMS and Manufacturing segments showed growth. The company aims to capitalize on new business opportunities in the biopharmaceutical sector.

Charles River Laboratories International, Inc. (NYSE: CRL) has launched viral vector reference materials to aid gene and cell therapy researchers, providing AAV and LVV products with high quality. The company aims to streamline the research and development process, offering superior serotypes and vector genome concentrations. The launch includes six AAV reference material serotypes and five LVV reference material products, contributing to their extensive CDMO offerings. The official launch will take place at the ASGCT Annual Meeting in May 2024, showcasing case study data and various presentations. Charles River's CGT portfolio and viral vector CDMO solutions aim to support client programs and assist in scaling from pre-clinical to commercial stages.